湖南省麦迪卡药石农业应用效果综述

湖南省麦迪卡药石(MEDCAL STONE)资源丰富,质量优良,具有富硅、富钾、富微量元素和离子轻稀土的特点,具有很强的吸附性能,可溶出多种有益矿物质,增加水中氧的含量,调节水的pH值,生物活性强,对防治疾病具有重要作用。经过近20 a的研究,农业上应用在作物施肥、药膳食疗等方面,均有极好的社会、经济效益。同时,产地水土、森林、人文资源特好,生态景观优美,不但是天然的无公害农业基地,也是发展休闲农业、旅游农业的"风水宝地"。     

Ontogenetic movements of juvenile blacktip reef sharks: evidence of dispersal and connectivity between coastal habitats and coral reefs

相似文献   

日光温室内反光膜补光的实践与理论探析

试验结果表明 ,温室后墙悬挂反光膜进行补光后 ,对温室内测定点处最大光照度值无影响 ,但平均提高测定点处水平光照度值 15 4 8% ;温室内凌晨时气温、地温、墙温和被反光膜遮掩处墙温分别比对照温室低 1 1℃、1 5℃、0 9℃和 1 8℃ ,但正午时分别比对照温室高 1 6℃、1 4℃、0 3℃和低 11 4℃。温室经济产量增加 7 4 % ,当期经济效益增加 2 1元 /m2 。     

不同栽培模式及施氮量对半旱地冬小麦氮素累积及分配的影响

【目的】研究不同栽培模式和施氮量对半旱地栽培条件下冬小麦-夏玉米轮作体系中冬小麦地上部氮素累积、分配及利用效率的影响。【方法】在陕西关中地区进行了田间试验,以常规栽培为对照,比较了补灌、覆草和垄沟等栽培模式及0,120,240 kg/hm2施氮水平,对冬小麦连续2年(2004和2005年)不同生长期各部位氮素累积量的影响。【结果】在补灌模式下,2004和2005年成熟期冬小麦叶片和茎秆的氮素累积量较其他模式低,氮素分配率也较低,而籽粒的氮素分配率较高;施用氮肥显著增加了各生长时期冬小麦叶片、茎秆、颖壳和穗轴以及籽粒的氮素累积量,当氮肥施用量由120增加到240 kg/hm2时,除籽粒外,成熟期冬小麦叶片、茎秆、颖壳和穗轴的氮素残留量均随之明显增加。与不同栽培模式相比,施用氮肥对冬小麦不同器官中氮素分配的影响较小。随着氮肥施用量的增加,氮肥利用效率、氮肥农学效率和氮肥生理效率均呈降低趋势。在不同栽培模式中,连续2年补灌栽培模式下冬小麦的氮肥利用效率、氮肥农学效率以及氮肥生理效率均较高,而其他栽培模式下这3个指标年际间的变化较大。【结论】施用氮肥可显著增加冬小麦各生长时期不同器官的氮素累积量,但对氮素在不同器官中分配比例的影响较小;与施用氮肥相比,不同栽培模式对冬小麦氮素的累积、分布无明显影响;冬季补灌有利于提高冬小麦的氮素效率。     

Prevention of experimentally induced heartworm (Dirofilaria immitis) infections in dogs and cats with a single topical application of selamectin

In a series of six controlled studies (four in dogs, two in cats), heartworm-free dogs and cats were inoculated with Dirofilaria immitis larvae (L(3)) prior to topical treatment with the novel avermectin selamectin or a negative control containing inert formulation ingredients (vehicle). Selamectin and negative-control treatments were administered topically to the skin at the base of the neck in front of the scapulae. In dogs, selamectin was applied topically at dosages of 3 or 6mgkg(-1) at 30 days post-inoculation (PI), or of 3 or 6mgkg(-1) at 45 days PI, or of 6mgkg(-1) at 60 days PI. Cats were treated topically with unit doses providing a minimum dosage of 6mgkg(-1) selamectin at 30 days PI. Of the animals that were treated 30 days PI, some dogs were bathed with water or shampoo between 2 and 96h after treatment, and some cats were bathed with shampoo at 24h after treatment. Between 140 and 199 days PI, the animals were euthanized and examined for adult D. immitis. Adult heartworms developed in all control dogs (geometric mean count, 18.7 worms) and in 88% of control cats (geometric mean count, 2.1 worms). Selamectin was 100% effective in preventing heartworm development in dogs when administered as a single topical dose of 3 or 6mgkg(-1) at 30 days after infection, 3 or 6mgkg(-1) at 45 days after infection, or 6mgkg(-1) at 60 days after infection. Selamectin was 100% effective against heartworm infections in cats when administered as a single topical unit dose of 6mgkg(-1). Bathing with water or shampoo between 2 and 96h after treatment did not reduce the efficacy of selamectin as a heartworm prophylactic in dogs. Likewise, bathing with shampoo at 24h after treatment did not reduce the efficacy of selamectin in cats. These studies demonstrated that, at the recommended dosage and treatment interval, a single topical administration of selamectin was 100% effective in preventing the development of D. immitis in dogs and cats.     

Safety of selamectin in dogs

Selamectin is a broad-spectrum avermectin endectocide for treatment and control of canine parasites. The objective of these studies was to evaluate the clinical safety of selamectin for topical use in dogs 6 weeks of age and older, including breeding animals, avermectin-sensitive Collies, and heartworm-positive animals. The margin of safety was evaluated in Beagles, which were 6 weeks old at study initiation. Reproductive, heartworm-positive, and oral safety studies were conducted in mature Beagles. Safety in Collies was evaluated in avermectin-sensitive, adult rough-coated Collies. Studies were designed to measure the safety of selamectin at the recommended dosage range of 6-12mgkg(-1) of body weight. Endpoints included clinical examinations, clinical pathology, gross and microscopic pathology, and reproductive indices. Selected variables in the margin of safety and reproductive safety studies were subjected to statistical analyses. Pups received large doses of selamectin at the beginning of the margin of safety study when they were 6 weeks of age and at their lowest body weight, yet displayed no clinical or pathologic evidence of toxicosis. Similarly, selamectin had no adverse effects on reproduction in adult male and female dogs. There were no adverse effects in avermectin-sensitive Collies or in heartworm-positive dogs. Oral administration of the topical formulation caused no adverse effects. Selamectin is safe for topical use on dogs at the recommended minimum dosage of 6mgkg(-1) (6-12mgkg(-1)) monthly starting at 6 weeks of age, and including dogs of reproducing age, avermectin-sensitive Collies, and heartworm-positive dogs.